Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim, MorphoSys Expand Antibody-development Collaboration

NEW YORK, March 18 (GenomeWeb News) - Boehringer Ingelheim has obtained from MorphoSys the option to exclusively license several therapeutic antibodies being co-developed by the firms under a previous agreement with the two companies, the company said today.

Under the agreement, which expands a previous therapeutic antibody collaboration between the two companies, Behringer will also obtain access to MorphoSys's HuCal Gold library, taking installation first at its site in Vienna.

Boehringer will pay MorphoSys an undisclosed technology access fee, annual licenses fees, and optional R&D funding over the 5-year term of the collaboration. It will also pay milestone fees and royalties for any therapeutic antibodies emerging from the collaboration.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.